Editorial: From molecular changes to behaviour: exploring neuropsychiatric disorders
Frontiers in Psychiatry · 22.06.2026 · 17
DOI: 10.3389/fpsyt.2026.1893034 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Psychiatry, online erschienen am 22.06.2026. Verfasst von Bruno Manadas und 2 weiteren Autor:innen. Beteiligte Einrichtung: CNC - Center for Neurosciences and Cell Biology, and CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Port…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Yang et al. combine RNA sequencing of peripheral blood mononuclear cells with an integrated machine-learning pipeline (LASSO, SVM-RFE, and Random Forest) to identify peripheral biomarkers of adolescent MDD. Their work converges on a three-gene panel (SLC4A1, IGF1, MMP9) that yields an area under the curve of 0.867 and simultaneously implicates an unexpected coexistence of hypoxic compensation and neurotrophic/remodeling failure in early-onset depression. The result is a striking illustration of how unbiased transcriptomics can refine diagnosis while reshaping pathophysiological hypotheses.Malekpour et al. address suicidality, one of psychiatry's most urgent yet least mechanistically understood phenotypes. Their systematic review and bioinformatic synthesis of human case-control studies converge on three recurrently dysregulated microRNAs (miR-30a, miR-30e, and miR-218) whose brain-expressed targets implicate FoxO and Rap1 signaling, long-term depression, and dopaminergic synapse function. Together, these findings delineate actionable biomarker and therapeutic target candidates for a phenotype that has resisted single-marker approaches.Kesebir and Demirer complement these omics-based efforts with an electrophysiological approach, integrating advanced information-theoretic measures of EEG dynamics (entropy-doubling, Ruzsa distance) with peripheral lactate levels in patients with mania-predominant bipolar disorder. Highbeta amplitude entropy emerges as the strongest and most consistent correlate of lactate, supporting a model of metabolic-oxidative dysregulation that bridges brain dynamics and mitochondrial bioenergetics and offering a quantitative biomarker framework at the interface of psychiatry and biomedical engineering.A second cluster of articles examines the mechanistic processes linking environmental and molecular insults to disease. Shkarina et al. review how chronic stress remodels the epigenome during critical developmental windows, altering the expression of genes that govern neural maturation and function.By cataloging the epigenetic modifiers and target genes most consistently implicated, they make the case for precision-medicine approaches operating at the epigenomic level, both as diagnostic strata and as therapeutic entry points.Rao et al. synthesize an evolving body of literature on the type-1 cannabinoid receptor (CB1R) as a shared substrate of psychosis in schizophrenia and Alzheimer's disease. They argue that CB1R functions as both a "friend" and a "foe". Its loss, whether driven by adolescent high-potency cannabis exposure, anandamide-driven internalization in first-episode psychosis, or age-related decline in Alzheimer's disease, is associated with psychotic symptomatology. Low-dose partial agonism appears to alleviate it. The paper weaves together cannabinoid pharmacology, epigenetic regulation of CNR1, and clinical findings into a coherent translational narrative.Lai et al. shift the focus to the subcellular scale, showing that the SENP3/FIS1 axis drives mitochondrial fragmentation in the prefrontal cortex of mice subjected to chronic unpredictable mild stress (CUMS) and that electroacupuncture at GV20/GV29 reverses this fragmentation alongside depression-like behavior. This study is an instructive example of how a non-pharmacological intervention can be mechanistically linked to a defined molecular pathway, with clear implications for circuit-and organelle-targeted therapeutics. Taken together, these ten contributions illustrate that progress in neuropsychiatric research depends on holding several scales in view at once: peripheral biomarker discovery alongside studies of synaptic and mitochondrial biology; animal and cellular models alongside human clinical and post-mortem data; and pharmacological alongside lifestyle and somatic interventions. They also remind us that the same molecular system (be it the endocannabinoid axis, mitochondrial dynamics, or the epigenome) may carry opposing prognostic and therapeutic implications, depending on the developmental window, disorder, and dose. We thank the authors for their thoughtful submissions, the reviewers for their rigorous critique, and the editorial staff of Frontiers in Psychiatry for their support throughout this Research Topic. We hope this collection encourages further multidimensional studies that continue to translate molecular changes into mechanistic understanding of behavior and, in time, into better lives for the people who live with these conditions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CNC - Center for Neurosciences and Cell Biology, and CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.
- BioMed X Institute, Heidelberg, Germany.
- Division of Physiological Genomics, BioMedical Center, Faculty of Medicine, Ludwig-Maximilians-Universität München, Planegg-Martinsried, Germany.
Zitieren
APA
Manadas, B., Santa, C., & Rodrigues, D. (2026). Editorial: From molecular changes to behaviour: exploring neuropsychiatric disorders. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1893034
Vancouver
Manadas B, Santa C, Rodrigues D. Editorial: From molecular changes to behaviour: exploring neuropsychiatric disorders. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1893034
BibTeX
@article{Manadas2026,
author = {Manadas, Bruno and Santa, Cátia and Rodrigues, Diana},
title = {Editorial: From molecular changes to behaviour: exploring neuropsychiatric disorders},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1893034}
}
EUVIMED